

## Users of prescription drugs (NHC) – users per 1000 inhabitants, age standardised

Year				2005	2006	2007	2008	2009	2010	2011	2012	2013	2014		
Geography	Drug group	Age	Gender												
Troms og Finnmark	Total all drug groups	0-74 yrs	both genders	631	635	641	652	664	651	651	650	644	641		
			men	559	562	573	584	599	581	584	582	575	569		
			women	709	713	713	725	735	725	724	724	720	719		
		0-44 yrs	both genders	552	557	559	572	587	568	567	564	557	553		
			men	465	469	479	491	509	482	486	482	472	465		
			women	644	650	645	658	670	660	654	654	650	649		
		0-17 yrs	both genders	400	409	403	423	449	426	423	422	413	411		
			men	386	394	395	412	439	411	416	413	406	400		
			women	415	425	411	436	461	443	432	433	422	424		
		18-24 yrs	both genders	641	642	651	655	665	648	652	642	636	637		
			men	450	450	468	474	492	465	471	464	446	449		
			women	847	847	846	846	852	849	850	842	849	849		
		25-44 yrs	both genders	645	648	656	665	673	656	656	654	648	640		
			men	534	537	552	560	572	547	548	544	535	524		
			women	762	766	767	777	780	773	770	771	769	765		
		45-74 yrs	both genders	771	774	784	793	800	796	800	800	798	795		
			men	723	725	739	748	756	754	757	757	755	752		
			women	823	825	832	841	847	841	845	846	843	841		
		0-79 yrs	both genders	638	643	648	660	672	658	659	658	652	649		
			men	568	572	583	593	608	590	594	591	585	580		
			women	714	718	718	730	740	731	729	730	726	725		
		18-79 yrs	both genders	712	714	724	732	740	730	732	730	726	722		
			men	623	626	640	649	660	646	648	646	639	635		
			women	805	808	812	821	826	819	821	821	819	817		
			Diabetes drugs (A10)	0-74 yrs	both genders	22	23	24	26	27	27	27	28	28	28



	men	2	2	2	2	2	2	3	3	3	3	
	women	1	1	2	2	2	2	2	2	2	2	
18-24 yrs	both genders	4	5	5	5	5	5	5	5	5	6	
	men	5	5	5	6	7	7	7	7	7	7	
	women	4	5	4	4	4	3	3	4	4	4	
25-44 yrs	both genders	7	7	7	7	7	7	7	8	8	8	
	men	7	7	8	8	8	8	7	8	8	8	
	women	7	7	7	7	7	7	7	7	7	8	
45-74 yrs	both genders	18	18	19	19	19	20	19	19	20	20	
	men	20	21	21	22	23	23	23	23	24	24	
	women	15	15	15	15	16	16	15	15	16	16	
0-79 yrs	both genders	10	10	10	11	11	11	11	11	11	11	
	men	11	11	12	12	12	13	13	13	13	13	
	women	9	9	9	9	9	9	9	9	10	10	
18-79 yrs	both genders	12	13	13	13	13	14	13	14	14	14	
	men	14	14	15	15	16	16	16	16	16	16	
	women	11	11	11	11	11	11	11	11	12	12	
Cardiovascular disease, treatment/prevention (C)	0-74 yrs	both genders	144	149	153	159	162	164	164	165	165	164
		men	143	148	152	160	163	165	165	166	167	166
		women	145	149	153	159	161	164	163	163	163	162
0-44 yrs	both genders	30	31	33	34	35	36	37	37	38	39	
	men	27	28	30	32	33	34	34	35	35	35	
	women	33	35	36	37	37	39	40	39	42	43	
0-17 yrs	both genders	5	6	6	6	7	8	8	10	10	10	
	men	6	7	7	7	8	9	9	11	11	11	
	women	4	5	5	5	6	8	8	9	8	10	
18-24 yrs	both genders	14	16	17	16	17	19	19	20	22	24	
	men	10	11	13	13	13	13	14	16	16	17	
	women	18	21	20	20	21	25	25	25	29	32	
25-44 yrs	both genders	55	58	60	63	64	65	65	65	67	67	

	men	49	51	54	58	60	61	61	62	62	60	
	women	62	64	66	68	67	70	70	69	73	75	
45-74 yrs	both genders	345	354	363	379	385	389	388	388	387	384	
	men	347	358	367	384	391	395	396	396	398	397	
	women	342	350	359	373	379	382	380	379	375	371	
0-79 yrs	both genders	158	163	168	175	177	180	180	180	181	180	
	men	157	163	167	175	178	180	181	182	183	182	
	women	159	163	168	174	177	179	179	178	178	178	
18-79 yrs	both genders	205	211	217	226	230	232	232	232	233	232	
	men	204	210	216	226	230	233	234	234	235	235	
	women	206	212	218	226	229	232	231	230	231	230	
Cardiovascular disease, treatment/prevention, except lipid modifying agents (C except C10)	0-74 yrs	both genders	129	132	135	140	141	142	141	142	143	142
		men	127	131	134	141	142	142	142	144	145	144
		women	130	133	136	139	140	141	139	139	141	141
0-44 yrs	both genders	27	29	30	31	31	32	33	34	35	36	
	men	23	24	26	27	28	28	29	31	31	31	
	women	31	33	34	34	35	36	37	37	39	41	
0-17 yrs	both genders	5	6	6	6	7	8	8	9	9	10	
	men	6	7	7	7	8	9	9	10	11	11	
	women	4	5	5	5	6	7	8	8	8	9	
18-24 yrs	both genders	13	15	16	15	16	18	19	19	21	24	
	men	9	10	12	12	12	12	13	15	15	17	
	women	18	20	20	19	21	24	24	25	28	31	
25-44 yrs	both genders	50	52	54	56	56	57	57	58	60	61	
	men	41	44	46	49	50	50	50	52	52	52	
	women	58	61	62	63	63	64	65	64	69	71	
45-74 yrs	both genders	307	314	320	332	334	333	330	331	332	329	
	men	310	319	326	340	342	343	341	343	344	342	
	women	304	309	314	323	325	324	319	319	318	315	
0-79 yrs	both genders	142	146	150	154	156	156	156	156	157	157	

		men	141	146	149	155	156	157	157	158	159	159
		women	144	147	150	154	155	156	154	154	155	155
	18-79 yrs	both genders	184	189	194	200	201	202	201	201	203	202
		men	183	188	193	200	202	202	202	204	205	204
		women	186	191	195	199	201	201	199	199	200	200
Lipid modifying agents (C10)	0-74 yrs	both genders	61	66	71	75	79	82	83	81	79	78
		men	69	74	78	84	87	91	91	90	89	88
		women	53	57	62	67	70	73	74	72	69	67
	0-44 yrs	both genders	5	5	6	7	7	8	7	7	7	6
		men	7	7	9	9	10	10	10	9	9	8
		women	3	3	4	4	5	5	5	4	4	4
	0-17 yrs	both genders	0	0	0	0	0	0	0	0	0	0
		men	:	:	:	:	:	:	:	:	:	:
		women	:	:	:	:	:	:	:	:	:	:
	18-24 yrs	both genders	1	1	1	1	1	1	1	1	1	1
		men	:	:	:	:	:	:	:	1	1	1
		women	:	:	:	:	:	:	:	1	1	1
	25-44 yrs	both genders	11	11	13	15	15	16	15	14	14	13
		men	14	15	18	20	21	22	21	20	19	17
		women	7	7	8	9	9	11	9	8	8	8
	45-74 yrs	both genders	160	172	183	196	205	213	215	212	207	203
		men	178	190	201	214	223	232	234	232	230	228
		women	141	151	164	176	186	193	195	191	184	177
	0-79 yrs	both genders	67	73	78	84	88	92	92	91	89	88
		men	:	:	:	:	:	:	:	100	99	99
		women	:	:	:	:	:	:	:	81	79	76
18-79 yrs	both genders	88	95	102	110	115	120	121	119	117	115	
	men	99	106	113	121	126	131	132	131	130	129	
	women	77	83	91	98	103	108	109	106	103	100	
Painkillers (analgetics) (M01A, N02A, N02B)	0-74 yrs	both genders	211	212	217	217	216	215	215	215	210	209

	men	187	187	193	194	193	191	192	188	183	181	
	women	236	238	241	241	240	241	240	244	240	239	
0-44 yrs	both genders	152	151	155	156	154	151	150	150	144	141	
	men	137	135	140	141	140	133	134	131	124	120	
	women	167	167	170	171	169	170	167	171	166	164	
0-17 yrs	both genders	26	26	27	28	27	28	29	29	26	27	
	men	21	21	23	23	23	23	25	25	22	21	
	women	32	31	33	32	31	34	33	35	29	33	
18-24 yrs	both genders	168	164	169	172	166	158	158	159	151	150	
	men	144	136	143	148	139	128	129	128	115	117	
	women	195	195	196	198	195	190	191	194	191	187	
25-44 yrs	both genders	248	248	254	255	254	249	246	245	238	232	
	men	228	228	235	235	235	224	224	218	209	202	
	women	269	270	273	276	273	274	269	275	269	264	
45-74 yrs	both genders	316	319	325	325	325	328	329	330	327	328	
	men	276	277	287	289	287	293	293	290	287	288	
	women	357	362	365	362	365	364	366	371	368	369	
0-79 yrs	both genders	215	216	220	221	220	219	219	219	214	213	
	men	190	190	196	198	197	194	195	192	186	185	
	women	240	242	245	245	245	245	244	248	244	243	
18-79 yrs	both genders	272	274	279	280	280	277	278	278	272	270	
	men	242	241	249	251	250	246	247	243	236	235	
	women	304	307	310	311	310	309	309	314	310	308	
Antiinflammatory and antirheumatic products, non-steroids (M01A)	0-74 yrs	both genders	169	168	170	170	168	165	162	161	152	148
		men	149	146	150	151	150	146	145	140	132	129
		women	191	190	190	189	186	185	180	182	174	169
	0-44 yrs	both genders	126	124	126	127	124	121	119	116	108	105
		men	113	110	114	115	113	106	107	102	93	91
		women	139	138	139	140	136	136	131	132	125	121
	0-17 yrs	both genders	23	21	23	23	22	23	22	23	19	20

	men	18	17	18	19	18	17	18	18	16	15	
	women	28	26	28	28	27	29	27	28	24	26	
18-24 yrs	both genders	142	137	140	143	135	128	124	124	113	111	
	men	122	113	119	122	112	105	103	99	85	88	
	women	163	163	162	165	159	153	148	151	144	137	
25-44 yrs	both genders	204	203	206	207	204	198	195	190	179	172	
	men	188	186	190	192	191	179	181	170	158	153	
	women	221	220	221	222	218	218	211	211	202	192	
45-74 yrs	both genders	246	245	246	244	244	243	238	239	229	224	
	men	212	209	214	214	215	217	211	209	200	195	
	women	282	283	279	275	275	271	266	270	259	254	
0-79 yrs	both genders	170	169	170	171	169	166	163	161	152	148	
	men	149	147	151	152	151	147	145	141	132	129	
	women	192	192	191	190	187	186	181	183	174	169	
18-79 yrs	both genders	216	214	216	216	214	210	206	204	193	188	
	men	190	187	192	193	191	186	185	179	168	164	
	women	242	242	241	240	237	234	228	230	220	213	
Painkillers, Opioids (N02A)	0-74 yrs	both genders	87	88	93	94	94	95	96	97	97	98
		men	79	80	85	85	86	87	88	87	87	87
		women	96	97	102	103	103	104	105	107	108	109
0-44 yrs	both genders	59	59	63	63	64	64	64	66	66	65	
	men	54	55	57	58	59	58	58	58	58	55	
	women	64	64	69	69	69	71	71	74	74	75	
0-17 yrs	both genders	5	6	6	6	7	7	9	9	8	8	
	men	4	5	5	5	6	7	8	9	8	7	
	women	6	6	7	7	8	8	9	10	8	9	
18-24 yrs	both genders	58	56	60	62	62	63	64	68	67	69	
	men	47	45	50	51	50	49	51	54	50	52	
	women	69	69	71	74	75	77	79	84	85	88	
25-44 yrs	both genders	102	104	110	110	111	112	110	111	112	109	

	men	96	99	102	102	104	103	101	100	101	96	
	women	109	110	118	118	118	121	119	123	124	124	
45-74 yrs	both genders	137	140	146	147	148	149	152	151	153	156	
	men	123	125	133	134	133	137	140	138	138	144	
	women	151	155	159	162	163	163	165	165	168	168	
0-79 yrs	both genders	90	91	95	97	97	98	99	99	100	100	
	men	81	82	87	87	88	89	90	89	89	90	
	women	99	100	105	106	106	107	108	110	111	111	
18-79 yrs	both genders	115	117	123	124	125	126	127	127	128	129	
	men	104	106	112	112	113	114	115	114	114	115	
	women	127	129	134	136	137	138	139	141	143	143	
Painkillers, other (N02B)	0-74 yrs	both genders	24	28	33	39	45	51	60	63	66	71
		men	19	21	26	31	36	41	47	50	50	54
		women	30	35	41	48	55	63	73	78	83	89
0-44 yrs	both genders	15	16	20	24	27	31	36	38	39	42	
	men	12	13	17	20	23	25	30	30	29	31	
	women	17	20	24	28	32	37	43	47	49	53	
0-17 yrs	both genders	3	3	4	4	4	5	6	6	5	6	
	men	3	2	3	3	3	4	5	5	5	5	
	women	3	3	4	4	5	6	7	7	6	8	
18-24 yrs	both genders	13	12	18	21	24	25	30	33	29	37	
	men	11	9	16	18	21	18	24	26	22	26	
	women	15	16	21	24	27	33	37	41	38	48	
25-44 yrs	both genders	25	29	35	41	48	54	63	66	69	72	
	men	20	24	28	34	40	43	52	51	52	54	
	women	29	35	42	49	56	64	75	82	87	91	
45-74 yrs	both genders	42	48	56	66	76	88	101	108	114	123	
	men	32	36	43	50	58	69	78	84	86	95	
	women	52	61	70	83	94	108	124	132	143	154	
0-79 yrs	both genders	26	30	36	42	47	54	63	66	69	74	



		men	20	23	28	33	38	42	50	52	52	57	
		women	32	37	44	51	57	66	76	81	86	93	
	18-79 yrs	both genders	33	38	45	53	61	69	80	85	88	95	
		men	26	29	35	42	48	54	63	66	67	72	
		women	40	48	56	65	74	84	97	104	110	119	
Antimigraine preparations (N02C)	0-74 yrs	both genders	17	18	18	19	19	19	19	19	20	20	
		men	6	7	7	7	7	7	7	7	7	8	
		women	29	30	31	31	31	32	32	32	32	34	34
	0-44 yrs	both genders	15	16	16	16	16	17	16	17	17	18	
		men	6	6	6	6	6	6	7	7	7	7	
		women	26	26	27	27	26	28	27	28	29	30	
	0-17 yrs	both genders	3	3	4	4	4	4	4	5	5	5	
		men	:	2	3	3	:	2	3	3	3	4	
		women	:	4	5	5	:	6	6	7	7	6	
	18-24 yrs	both genders	14	15	16	16	16	17	16	17	19	20	
		men	:	5	6	7	:	6	7	7	6	7	
		women	:	26	27	27	:	29	27	28	34	34	
	25-44 yrs	both genders	26	26	27	26	26	27	26	26	27	28	
		men	9	10	9	10	10	9	10	10	10	10	
		women	43	43	45	44	43	45	44	44	46	48	
	45-74 yrs	both genders	21	22	22	23	23	23	24	24	25	25	
		men	8	8	8	8	8	8	8	8	8	9	
		women	36	37	37	39	39	39	41	41	43	42	
	0-79 yrs	both genders	17	17	18	18	18	19	19	19	20	20	
		men	:	7	7	7	:	7	7	7	7	7	
		women	:	29	30	31	:	31	31	32	33	34	
18-79 yrs	both genders	21	22	22	23	23	23	23	24	24	25		
	men	7	8	8	8	8	8	8	8	8	8		
	women	36	37	38	39	38	39	39	39	42	42		
Drugs for mental disorders, incl. hypnotics (N05A, N05C, N05B, N06A)	0-74 yrs	both genders	52	52	52	52	53	53	53	54	54	53	



	men	1	1	1	1	1	1	1	1	1	1	
	women	1	1	1	1	1	1	1	1	1	1	
18-24 yrs	both genders	10	12	10	10	12	11	11	12	11	11	
	men	10	11	10	9	11	10	9	11	10	10	
	women	11	12	11	12	13	12	13	13	13	13	
25-44 yrs	both genders	20	20	19	19	20	19	20	19	19	18	
	men	20	20	19	20	21	19	20	19	20	19	
	women	21	21	20	19	19	19	19	19	19	18	
45-74 yrs	both genders	32	32	30	29	29	29	28	28	27	27	
	men	27	27	26	25	25	25	24	24	23	23	
	women	36	37	35	34	33	33	32	32	31	30	
0-79 yrs	both genders	19	20	19	18	19	18	18	18	17	17	
	men	17	18	17	16	17	16	16	16	16	15	
	women	21	22	21	20	20	20	19	19	19	18	
18-79 yrs	both genders	25	25	24	24	24	23	23	23	22	22	
	men	23	23	21	21	22	21	21	21	20	20	
	women	27	28	27	26	26	26	25	25	24	23	
Antidepressants (N06A)	0-74 yrs	both genders	39	39	40	40	41	41	42	43	43	43
		men	27	27	28	28	29	29	29	30	30	29
		women	52	52	53	53	54	54	56	56	57	57
0-44 yrs	both genders	26	26	27	27	28	29	30	30	30	29	
	men	19	19	19	20	20	21	22	22	22	20	
	women	33	34	34	35	36	36	38	40	40	39	
0-17 yrs	both genders	1	1	1	1	2	2	2	2	3	2	
	men	1	1	1	1	1	1	1	2	2	1	
	women	2	2	2	2	2	2	3	3	4	3	
18-24 yrs	both genders	23	24	26	28	30	30	32	35	33	35	
	men	15	15	16	17	19	21	20	22	19	20	
	women	31	33	36	40	42	41	44	49	49	51	
25-44 yrs	both genders	47	47	47	48	49	50	51	52	52	50	

	men	35	36	35	36	36	38	38	38	39	36	
	women	59	60	60	60	62	62	65	66	67	65	
45-74 yrs	both genders	61	62	63	63	64	64	65	64	65	66	
	men	40	40	42	42	43	43	43	44	44	45	
	women	84	84	85	85	85	86	87	86	88	88	
0-79 yrs	both genders	40	40	41	42	42	43	43	44	44	44	
	men	27	27	28	29	29	30	30	31	30	30	
	women	53	53	54	55	55	56	57	58	59	58	
18-79 yrs	both genders	52	52	53	54	54	55	56	56	57	56	
	men	35	36	37	37	38	39	39	39	39	38	
	women	68	69	70	71	72	72	74	74	76	75	
Hypnotics, sedatives and anxiolytics (N05C, N05B)	0-74 yrs	both genders	80	82	83	85	87	84	85	83	84	83
		men	57	60	61	63	65	64	64	63	64	63
		women	104	104	105	109	110	106	106	105	105	104
0-44 yrs	both genders	39	40	41	43	46	44	45	45	46	46	
	men	31	32	34	36	39	38	38	39	39	39	
	women	48	48	49	50	53	51	52	52	53	54	
0-17 yrs	both genders	7	8	8	8	9	9	10	10	11	12	
	men	7	8	9	9	9	10	11	11	12	13	
	women	7	7	7	7	9	8	9	9	10	11	
18-24 yrs	both genders	31	33	34	37	41	37	40	42	42	42	
	men	22	23	25	29	30	28	31	33	32	33	
	women	40	44	43	46	53	47	49	54	54	53	
25-44 yrs	both genders	68	69	71	74	77	75	74	75	75	75	
	men	53	55	58	61	66	64	62	63	63	62	
	women	84	83	85	87	90	87	87	87	88	89	
45-74 yrs	both genders	151	154	156	160	159	155	155	150	151	147	
	men	103	108	109	110	111	110	110	106	108	104	
	women	201	203	204	212	209	203	203	197	196	193	
0-79 yrs	both genders	85	87	88	91	92	90	90	88	88	88	

		men	61	64	65	67	69	68	68	67	67	66
		women	110	111	112	116	116	113	113	111	111	110
	18-79 yrs	both genders	110	112	113	117	118	115	115	112	112	111
		men	78	81	83	85	87	86	86	84	84	82
		women	142	143	145	149	149	145	145	142	142	141
Hypnotics, addictive (N05C excl. N05CH01 and N05CD08)	0-74 yrs	both genders	51	53	53	55	55	54	53	51	50	48
		men	36	38	39	40	40	39	39	37	36	35
		women	68	69	69	72	71	69	69	65	64	63
	0-44 yrs	both genders	22	23	23	24	25	24	24	22	22	21
		men	17	18	19	20	21	19	20	18	18	17
		women	28	28	27	29	29	28	28	27	26	26
	0-17 yrs	both genders	1	1	1	1	2	1	1	1	1	1
		men	1	1	1	1	1	1	1	1	1	0
		women	1	1	1	1	2	1	2	1	1	1
	18-24 yrs	both genders	17	18	16	21	21	19	19	18	17	16
		men	12	11	13	16	15	13	13	13	11	12
		women	23	25	20	26	27	25	24	23	23	21
	25-44 yrs	both genders	41	42	42	45	45	44	43	41	40	39
		men	32	34	35	37	39	37	37	34	34	32
		women	50	50	50	53	52	51	50	49	47	47
	45-74 yrs	both genders	103	106	107	110	108	107	106	100	99	96
		men	69	72	74	75	74	74	73	69	69	66
		women	138	142	142	147	143	141	140	133	132	128
	0-79 yrs	both genders	56	57	58	60	60	58	58	55	54	52
		men	39	41	42	43	44	43	42	40	39	37
		women	73	74	74	77	76	75	74	70	69	68
18-79 yrs	both genders	72	75	75	78	77	76	75	71	70	68	
	men	51	53	55	56	57	56	55	52	51	49	
	women	94	97	96	101	98	97	96	91	90	88	
ADHD drugs (Attention Deficit Hyperactivity Disorder) (C02AC02 and N06BA except N06BA07)	0-74 yrs	both genders	3	4	4	5	5	6	6	6	7	7

	men	4	5	6	6	7	7	8	8	8	9	
	women	2	2	3	3	4	4	4	4	5	5	
0-44 yrs	both genders	5	5	7	7	8	8	9	9	10	10	
	men	7	8	9	9	10	11	11	12	12	13	
	women	3	3	4	5	5	6	6	6	7	7	
0-17 yrs	both genders	9	9	11	12	12	13	14	14	14	15	
	men	13	14	16	17	18	18	20	21	21	21	
	women	4	5	6	7	7	7	7	7	7	8	
18-24 yrs	both genders	4	5	7	8	9	9	9	11	10	11	
	men	6	7	9	9	9	9	10	10	9	11	
	women	2	3	5	7	9	9	9	11	12	12	
25-44 yrs	both genders	2	2	3	3	4	4	4	5	5	6	
	men	2	3	3	3	4	5	5	5	6	7	
	women	1	1	2	3	3	4	4	4	5	6	
45-74 yrs	both genders	0	0	0	1	1	1	1	1	1	2	
	men	0	0	0	1	1	1	1	1	1	2	
	women	0	0	0	0	1	1	1	1	1	1	
0-79 yrs	both genders	:	:	:	:	:	:	:	:	:	:	
	men	:	:	:	:	:	:	:	:	:	:	
	women	:	:	:	:	:	:	:	:	:	:	
18-79 yrs	both genders	:	:	:	:	:	:	:	:	:	:	
	men	:	:	:	:	:	:	:	:	:	:	
	women	:	:	:	:	:	:	:	:	:	:	
Asthma and chronic obstructive pulmonary disease (COPD) drugs (R03 except R03CA)	0-74 yrs	both genders	73	73	74	77	77	80	81	83	82	82
		men	66	66	67	71	72	74	74	76	75	75
		women	80	81	81	83	84	86	88	90	89	89
0-44 yrs	both genders	60	61	62	65	65	67	68	69	67	67	
	men	59	59	60	65	64	67	66	68	66	66	
	women	61	62	64	66	65	68	70	70	69	68	
0-17 yrs	both genders	69	71	72	77	76	82	81	83	79	77	

	men	80	80	81	88	88	94	93	95	90	90	
	women	56	61	62	66	64	69	70	70	68	65	
18-24 yrs	both genders	52	53	52	53	55	53	54	55	55	56	
	men	43	45	42	46	49	48	47	49	47	47	
	women	61	61	62	62	61	59	62	62	63	65	
25-44 yrs	both genders	56	56	57	59	59	60	62	63	61	62	
	men	47	47	49	52	51	52	51	53	52	54	
	women	66	65	66	67	68	70	73	73	71	71	
45-74 yrs	both genders	95	95	95	97	100	101	103	106	108	108	
	men	78	78	78	81	84	86	87	89	90	91	
	women	113	113	112	113	116	118	120	125	126	127	
0-79 yrs	both genders	75	76	76	79	80	82	83	85	84	84	
	men	68	69	69	73	74	77	76	79	77	78	
	women	82	83	83	85	86	88	90	92	92	91	
18-79 yrs	both genders	77	77	77	80	81	82	84	86	86	86	
	men	65	65	66	69	70	71	71	73	73	74	
	women	91	90	90	91	93	94	96	99	99	100	
Antihistamines (allergy medicines) (R06A, R01AC, R01AD, R01B, S01G)	0-74 yrs	both genders	118	119	122	125	126	125	127	129	130	135
		men	95	96	100	103	104	102	103	103	104	108
		women	142	143	146	148	150	150	152	157	158	164
0-44 yrs	both genders	115	115	118	118	120	117	119	119	120	125	
	men	100	101	105	106	107	103	104	101	104	108	
	women	131	131	132	131	134	132	135	137	138	144	
0-17 yrs	both genders	94	94	92	92	93	89	92	90	92	95	
	men	101	101	102	102	104	99	101	96	99	104	
	women	86	86	82	81	82	79	83	83	85	85	
18-24 yrs	both genders	121	122	130	127	131	122	132	128	128	133	
	men	97	100	107	106	106	99	106	104	101	106	
	women	146	146	155	149	157	148	160	154	157	164	
25-44 yrs	both genders	131	131	136	136	138	137	136	139	141	147	

	men	100	101	108	109	109	107	106	104	108	112	
	women	163	162	165	166	169	169	168	176	175	185	
45-74 yrs	both genders	122	125	129	137	138	140	142	148	148	152	
	men	86	87	90	98	99	100	102	106	105	109	
	women	161	166	171	177	178	182	183	193	194	198	
0-79 yrs	both genders	118	119	122	124	126	125	127	129	130	135	
	men	95	96	100	103	104	102	103	103	104	108	
	women	142	143	146	147	150	150	152	157	158	163	
18-79 yrs	both genders	125	126	131	134	136	136	138	141	142	147	
	men	93	94	99	103	104	103	104	105	106	109	
	women	159	160	165	168	171	172	173	180	181	187	
Antihistamines for systemic use (R06)	0-74 yrs	both genders	87	89	90	91	90	88	90	90	92	97
		men	69	70	72	73	73	70	72	70	72	76
		women	106	109	109	110	109	107	110	112	114	120
0-44 yrs	both genders	89	91	91	90	89	85	87	86	88	94	
	men	79	80	82	82	81	76	78	75	77	81	
	women	100	102	100	99	98	95	97	98	100	107	
0-17 yrs	both genders	81	83	80	80	79	73	76	75	77	80	
	men	88	89	89	89	88	81	83	80	83	87	
	women	74	76	71	71	70	65	68	69	70	73	
18-24 yrs	both genders	97	97	104	99	99	90	98	94	95	100	
	men	79	80	86	84	83	72	83	76	75	79	
	women	116	116	123	116	117	109	115	113	117	124	
25-44 yrs	both genders	94	95	96	95	94	93	93	93	95	103	
	men	72	73	75	75	74	72	73	70	73	78	
	women	116	118	117	117	115	115	114	118	119	130	
45-74 yrs	both genders	83	86	89	92	92	93	95	98	99	104	
	men	51	53	55	58	59	59	60	62	64	67	
	women	116	122	125	129	127	128	132	135	137	143	
0-79 yrs	both genders	86	88	90	90	90	88	90	90	92	97	



		men	68	69	72	72	72	69	71	70	72	75
		women	106	108	109	109	109	107	110	112	113	120
	18-79 yrs	both genders	88	90	93	94	93	92	94	95	97	102
		men	62	64	67	67	67	66	68	67	68	72
		women	115	118	120	121	121	120	122	125	127	134

### CellMark Legend

- .. Missing data
- . Not possible to calculate
- : Hidden value

### Description

Users of prescription drugs among 0-79 year olds. Users are defined as people who have been dispensed at least one prescription in the reporting period.

Four measures are available. Use the Measures menu to select:

1. number of users (shown on national level only due to privacy protection)
2. users per 1000 = number of users per 1000 inhabitants of same sex and age per year
3. users per 1000 age standardized = number of users per 1000 inhabitants of same sex and age per year, age standardised. Age standardisation of rates reduces the effect of differing age distributions when groups are compared over time and between geographical regions.
4. Ratio (Norway=100): The ratio between the standardized rate in the county and the national rate for a given year. A ratio of 130 means that the county rate is 30 % higher than the national rate. A ratio of 87 means that the county rate is 13 % lower than the national level.

In the Norwegian Prescription Database, every individual is registered with a pseudonymous serial number which makes it possible to link drug consumption to individuals without knowing who they are. Even if a person has dispensed a prescription for the same drug several times, they are only counted as a user once.

Drug consumption cannot be assumed to be synonymous with disease prevalence. The exception is the use of drugs to treat diabetes mellitus, which can be considered a good indicator for prevalence of diabetes. A lot of patients use multiple drugs, e.g. both anti-depressives and hypnotics, so will be included in both groups. It is therefore not possible to simply add the number of users in two groups of drugs to find out how many users there are in total.

Figures in Norhealth may vary slightly from the Norwegian Prescription Database because data may have been extracted from the main database at different times.

Drugs are classified according to the ATC system (see below).

The following groups of drugs are included \*:

All drugs in total

Diabetes drugs (A10)

- Insulins and analogues (A10A)

Cardiovascular disease, treatment/prevention (C)

- Cardiovascular disease, treatment/prevention, except Lipid modifying agents (C except C10)

- Lipid modifying agents (C10)

Painkillers (analgetics) (M01A, N02A, N02B)

- Antiinflammatory and antirheumatic products, non-steroids (M01A)

- Painkillers, Opioids (N02A)

- Painkillers, other (N02B)

- Antimigraine preparations (N02C)

Drugs for mental disorders (N05A, N06A)

- Antipsychotics (N05A)

- Antidepressants (N06A)

Hypnotics and anxiolytics (N05B, N05C)

- Hypnotics (N05C)

- Hypnotics, addictive (N05C excl. N05CH01 and N05CD08)

ADHD drugs (Attention Deficit Hyperactivity Disorder) (C02AC02 and N06BA except N06BA07)

Asthma and chronic obstructive pulmonary disease (COPD) drugs (R03 except R03CA)

Antihistamines (allergy medicines) (R06A, R01AC, R01AD, R01B, S01G)  
- Antihistamines for systemic use (R06A)

Prescriptions for antibiotics are presented in a separate, neighbouring table.  
Data on Blood glucose lowering drugs, excluding insulins (A10B) are presented under Health and disease/ Disease groups/ Type 2 diabetes, indicators.

News, March 2019:

- New subgroup: Hypnotics, addictive - comprising all hypnotics except melatonin and midazolam.
- ADHD drugs now include guanfacin (C02AC02).
- Drugs against asthma and chronic obstructive pulmonary disease (COPD) now exclude R03CA. The former group "Asthma and COPD (R03)" has been discontinued.

Drugs are classified according to the ATC-system (Anatomic, Therapeutic, Chemical classification). By using this international classification system one can make statistics of drug consumption groups at 5 different levels, including from figures that show total use of all preparations classified under a main group (1st level, e.g. group C - Heart and circulation), figures for the different sub-groups (2nd, 3rd and 4th level) and down to figures that show use of each active ingredient.

Further information about the Norwegian Prescription Database can be found at [www.norpd.no](http://www.norpd.no).  
See also Drug Consumption in Norway at [www.drugconsumption.no](http://www.drugconsumption.no).

\* Some of the drugs can be bought without a prescription, e.g. in small packages. Such use is not included in the statistics.

---

### **Rationale for indicator**

For many diseases, we have insufficient data on prevalence. Drug use is not synonymous with disease prevalence, but can be an indicator for the prevalence of a disease.

---

### **Source**

Norwegian Institute of Public Health, Department of Pharmacoepidemiology

---

### **Collection**

The Norwegian Prescription Database contains information on all prescriptions dispensed from Norwegian pharmacies for both human and animal use. The register only contains information that directly or indirectly concerns prescriptions. Information about the patient and prescriber is pseudonymous.

---

### **Interpretation and sources of error**

Purchases of over the counter drugs from a pharmacy or grocery store are not included. People over 80 years are excluded because there are varying proportions in each county who live at institutions where drugs are provided by the institution rather than via private prescriptions. Figures are also not presented for inappropriate combinations of age and drug groups, for example anti-dementia medicines for children.

---

### **Data quality**

The data quality is very good.

---

### **Statistical analysis**

Age standardization is done using direct standardization. The standard population is the sum of men and women in each age group in Norway per 1.January 2012.

---

### **When numbers are missing**

Statistics based on fewer than five cases are hidden for privacy reasons. The same is done where the population segment from which the data are collected is less than ten.

If more than 20 per cent of the numbers in a time series are hidden for privacy reasons, the entire time series is concealed so as not to create a false impression of the situation in the county. Time series are also hidden where more than 50 per cent of the numbers in the time series are based on 6 or fewer cases.

---

### **Time periods**

2005-2021

---

### **Geographical level**

Country, health region, counties

---

### **Gender**

Both genders, men, women

---

### **Age groups**

0-74 years, 0-44 years (0-17, 18-24, 25-44), 45-74 years. Additionally, 0-79 years and 18-79 years.

---

### **Frequency of updates**

Annually

---

### **Last updated**

4/27/22

---

### **Keywords**

Click on a keyword to search for similar indicators.

- Antibiotics
  - Antihypertensives
  - Antipsychotics
  - Anxiety
  - Asthma
  - Betablockers
  - Blood lipids
  - Blood pressure
  - Blood sugar
  - Calcium antagonists
  - Cholesterol
  - Contraceptives
  - Dementia
  - Diabetes
  - Drugs
  - Estrogen
  - Hypertension
  - Hypnotics
  - Insulin
  - Medicine
  - Menopause
  - Obesity
  - Prescription database
  - Sedatives
- 

### **Fact sheets**

Below are links to relevant fact sheets, articles and reports. These may describe trends over time in the Norwegian population or differences by sex, age group, geographical region or socioeconomic status:

- [Topic: Drug consumption](#)
- [Topic: Pain](#)
- [Facts on hypertension \(in Norwegian only\)](#)
- [Chronic Obstructive Pulmonary Disease \(COPD\) in Norway - Public Health Report](#)